14 October 2022>: Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint 12ABCDEFG* , Jill M. Kolesar 23CDE , Joseph Robert McCorkle 2CDE , Jianrong Wu 4C , Carleton S. Ellis 23CDE , Danielle E. Otto 23CDE , Peng Wang 12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 5 Correlation between 1-month, 3-month, and 7-month abiraterone trough levels and prostate-specific antigen alteration (change from baseline to 1 month of starting treatment).
Correlation (PSA alternation, AA) | Spearman rank correlation | P value |
---|---|---|
1 Month | 0.372 | 0.259 |
3 Months | 0.183 | 0.637 |
7 Months | 0.200 | 0.704 |
PSA alteration, change of PSA from baseline to 1 month after treatment; AA – abiraterone acetate. |